In an interview with PharmaShots, Fred David Mast, Senior Research Scientist at Seattle Children’s Research Institute shared his views on the study demonstrating that Nanobodies could be an exceptional resource for superior COVID-19 protective and therapeutic interventions. The results of this study were published in E-life Shots: Seattle Children’s Research Institute’s scientists collaborated with researchers from Rockefeller University to investigate the…

In an interview with PharmaShots, Elke Walter, Senior Director, Global Zika Program Lead & Derek Wallace, Vice President, Global Dengue Program Lead at Takeda share their views on TAK-003 & highlighted 10 presentations from dengue and zika programs at ASTMH Shots: The company reported a cumulative safety assessment included long-term safety data from the five…

In an interview with PharmaShots, John C. Hairston, Sr. Medical Director, Oncology US Medical Affairs & Gabriel P. Haas, Senior Medical Director, Oncology Development Medical Sciences at Astellas share their views on the data of Xtandi (enzalutamide) over Active Surveillance for Localized Prostate Cancer Shots: The P-II (ENACT) study evaluates enzalutamide as monothx. vs active…

In an interview with PharmaShots, Adrian Hill, Head of Commercial Operations & Christian Weidenfeller, Global Head of Medical Affairs Anti-Infectives at Tillotts Pharma share their views on the ESCMID recommendation for Dificlir (fidaxomicin) to treat Clostridioides Difficile Infection Shots: ·        Clostridioides difficile infection (CDI) is the leading cause of hospital-acquired infection · …